GNI's pirfenidone set for Chinese launch for IPF
This article was originally published in Scrip
GNI Group has overcome one of the main remaining hurdles to the commercialization of its antifibrotic agent pirfenidone (F647) for adult idiopathic pulmonary fibrosis (IPF) in China, receiving an important regulatory approval for its Beijing Continent Pharmaceuticals subsidiary.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.